Aktiesnakken — Oktober 2010
-
I er godt klarover det er den samme meddelelse som ns steg 40% på. Bare et år længere fremme!
-
LifeCycle Pharma offentliggør dosering af første patient i pivotalt fase 3 studie af LCP-Tacro
i nytransplanterede (de novo) nyrepatienter -
det er røv og nøgler
-
den første patient er begyndti behandling
-
anmik, huset går ind for open source...:-)
-
yep jeg er med....
-
blot som eksempel denne .. har jo fremhævet Torm et par gange .. men link her tyder på ny nedtur .. såhh .. http://www.euroinvestor.dk/redirect.aspx?http://www.teknisk-analyse.dk/blog/index.php?category=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
